98%
921
2 minutes
20
Cortical tubers are malformations of cortical development in patients with tuberous sclerosis complex (TSC), and highly associated with pediatric intractable epilepsy. Recent evidence has shown that signaling mediated through vascular endothelial growth factor-C (VEGF-C) and its receptors, VEGFR-2 and VEGFR-3, has direct effects on both neurons and glial cells. To understand the potential role of VEGF-C system in the pathogenesis of cortical tubers, we investigated the expression patterns of VEGF-C signaling in cortical tubers compared with age-matched normal control cortex (CTX). We found that VEGF-C, VEGFR-2 and VEGFR-3 were clearly upregulated in tubers at both the mRNA and protein levels, compared with CTX. The in situ hybridization and immunostaining results demonstrated that VEGF-C, VEGFR-2 and VEGFR-3 were highly expressed in dysplastic neurons (DNs), giant cells (GCs) and reactive astrocytes within tubers. Most DNs/GCs expressing VEGF-C and its receptors co-labeled with neuronal rather than astrocytic markers, suggesting a neuronal lineage. In addition, protein levels of Akt-1, p-Bad and ERK1/2, the important downstream factors of the VEGF-C pathway, were significantly increased in cortical tubers, indicating involvement of VEGF-C-dependent prosurvival signaling in cortical tubers. Taken together, our results suggest a putative role for the VEGF-C signaling pathway in the pathogenesis of cortical tubers.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029110 | PMC |
http://dx.doi.org/10.1111/j.1750-3639.2011.00519.x | DOI Listing |
Clin Pharmacol Ther
August 2025
Centre for Human Drug Research, Leiden, The Netherlands.
Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD.
View Article and Find Full Text PDFFront Neurol
August 2025
Department of Pediatrics, Peking University People's Hospital, Beijing, China.
Background: This study developed and validated an interpretable machine learning (ML) algorithm for predicting the risk of drug-resistant epilepsy (DRE) in children with Tuberous sclerosis (TSC).
Methods: To estimate the risk of DRE in pediatric TSC patients, an interpretable ML model was developed and validated. Clinical data were retrospectively collected from 88 pediatric patients with TSC-related epilepsy.
J Family Med Prim Care
July 2025
Department of Pediatrics, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.
Tuberous sclerosis (TS) is a rare genetic disorder of autosomal-dominant inheritance. Mutations on either of the two genes Tuberous Sclerosis Complex 1 (TSC1) or Tuberous Sclerosis Complex 2 (TSC2) will lead to hamartomas formation involving many organs, such as the brain, heart, kidneys, skin, lungs, and liver. This case report is about an 11-month-old boy with epilepsy and hypomelanotic macules.
View Article and Find Full Text PDFInt J Mol Sci
July 2025
National Clinical Research Center for Child Health and Disorders, Chongqing 400014, China.
Tuberous sclerosis complex (TSC) is a systemic disease caused by mutations in either the TSC1 (encoding hamartin) or TSC2 (encoding tuberin) gene, with mutations in the TSC2 gene potentially leading to more severe clinical symptoms. Neurological symptoms are a common clinical manifestation of TSC, and neuroinflammation is thought to play an important role. Glial cells are a major source of neuroinflammation, but whether microglia are involved in the activation of the NOD-like receptor protein 3 (NLRP3) inflammasome and the expression of interleukin-1β (IL-1β) in TSC patients remains unclear.
View Article and Find Full Text PDFBackground: In the fifteen years since the first patient with drug-resistant epilepsy was treated by MR - guided laser interstitial thermal therapy (LITT) it has revolutionized the surgical treatment of epilepsy. Therapeutic targets have ranged from every form of epileptogenic lesion, including mesial temporal sclerosis (MTS), hypothalamic hamartomas (HH), malformations of cortical development, low-grade epilepsy associated tumors, and cerebral cavernous malformations (CCM), to MRI-normal epileptogenic zones characterized by stereo-electroencephalography (SEEG), to disconnection surgeries such as corpus callosotomy and even functional hemispherotomy. Many series now support the general effectiveness and safety of LITT for epilepsy although we are still in the period where increasing experience and technical advances are driving refinement in the therapy.
View Article and Find Full Text PDF